Gab1 is a docking protein that is downstream of multiple receptor tyrosine kinases (RTKs). Our goals are to further understand the role of Gab1 in EGF receptor and reactive oxygen species (ROS) signaling and how it participates in the process of gliomagenesis. We have shown that Gab1 can be a substrate for the SHP-2 tyrosine phosphatase and this interaction is essential for cell growth and transformation in NIH3T3 cells. In contrast, under oxidative stress we find that the Gab1/SHP-2 complex promotes cell death and is correlated with JNK activation. For the first time, we have observed that Gab1 is overexpressed in high grade astrocytoma tumors in comparison with normal glia, suggesting a role for Gab1 in gliomagenesis. It also presents two different patterns of localization, one diffuse and the other an unusual vesicular staining at the periphery which increases in frequency with tumor grade.
In Specific Aim #1, we will study the role of Gab1 in cell growth and transformation by: 1) analyzing the sites in Gab1 dephosphorylated by SHP-2; 2) using this information to identify the pathways downstream of the Gab1/SHP2 interaction responsible for cell growth and/or transformation.
Specific Aim #2 will focus on its role in ROS stimulation by :1) studying the localization of Gab1/SHP2 interaction after oxidative stress via FRET and cell fractionation; 2) the phosphorylation sites of Gab1 after H2O2 addition as revealed by MS-MALDI; and 3) how JNK is specifically activated by the Gab1/SHP-2 interaction.
In Specific Aim #3, we will examine the role of Gab1 in astrocytomas by studying: 1) if knock down of Gab1 expression in grade III and grade IV cell lines impairs tumorigenicity; 2) if the presence of Gab1 correlates with grade IV tumors arising from the secondary pathway; and 3) what is the nature of the vesicle-like structure where Gab1 is localized. This work will apply state of the art tools that have not been extensively used in cancer cells and may reveal new aspects of how cellular localization correlates with signaling and unique properties of signaling molecules in tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069495-12
Application #
7243508
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Jhappan, Chamelli
Project Start
1996-04-15
Project End
2010-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
12
Fiscal Year
2007
Total Cost
$315,940
Indirect Cost
Name
Stanford University
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Emlet, David R; Gupta, Puja; Holgado-Madruga, Marina et al. (2014) Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res 74:1238-49
Del Vecchio, C A; Giacomini, C P; Vogel, H et al. (2013) EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene 32:2670-81
Piccione, E C; Lieu, T J; Gentile, C F et al. (2012) A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors. Oncogene 31:2953-67
Nitta, R T; Del Vecchio, C A; Chu, A H et al. (2011) The role of the c-Jun N-terminal kinase 2-?-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene 30:234-44
Monje, Michelle; Mitra, Siddhartha S; Freret, Morgan E et al. (2011) Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A 108:4453-8
Gupta, Puja; Han, Shuang-Yin; Holgado-Madruga, Marina et al. (2010) Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol 10:72
Li, Gordon; Mitra, Siddhartha; Wong, Albert J (2010) The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. Neurosurg Clin N Am 21:87-93
Li, Gordon; Mitra, Siddhartha; Karamchandani, Jason et al. (2010) Pineal parenchymal tumor of intermediate differentiation: clinicopathological report and analysis of epidermal growth factor receptor variant III expression. Neurosurgery 66:963-8; discussion 968
Nitta, Ryan T; Badal, Shawn S; Wong, Albert J (2010) Measuring the constitutive activation of c-Jun N-terminal kinase isoforms. Methods Enzymol 484:531-48
Nitta, Ryan T; Chu, Albert H; Wong, Albert J (2008) Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation. J Biol Chem 283:34935-45

Showing the most recent 10 out of 27 publications